-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, QXo6hSC1+mJKE8UCiGVDKkj2gRMBkAWTbetiez/dJHwu0nQiCn+a5lcDqPQy17Mg OPKPIR6gB482FVhZvp0NRg== 0001179110-10-014092.txt : 20100922 0001179110-10-014092.hdr.sgml : 20100922 20100922091350 ACCESSION NUMBER: 0001179110-10-014092 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20100922 FILED AS OF DATE: 20100922 DATE AS OF CHANGE: 20100922 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: CONRAD HERBERT J CENTRAL INDEX KEY: 0001218815 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-15006 FILM NUMBER: 101083893 MAIL ADDRESS: STREET 1: 134 LOWELL RD CITY: GLEN ROCK STATE: NJ ZIP: 07452 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Celldex Therapeutics, Inc. CENTRAL INDEX KEY: 0000744218 STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835] IRS NUMBER: 133191702 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 119 FOURTH AVE CITY: NEEDHAM STATE: MA ZIP: 02494 BUSINESS PHONE: 7814330771 MAIL ADDRESS: STREET 1: 119 FOURTH AVE CITY: NEEDHAM STATE: MA ZIP: 02494-2725 FORMER COMPANY: FORMER CONFORMED NAME: AVANT IMMUNOTHERAPEUTICS INC DATE OF NAME CHANGE: 19980828 FORMER COMPANY: FORMER CONFORMED NAME: T CELL SCIENCES INC DATE OF NAME CHANGE: 19920703 4 1 edgar.xml FORM 4 - X0303 4 2010-09-22 0 0000744218 Celldex Therapeutics, Inc. CLDX 0001218815 CONRAD HERBERT J C/O CELLDEX THERAPEUTICS, INC. 119 FOURTH AVENUE NEEDHAM MA 02494 1 0 0 0 Common Stock 2010-09-22 4 A 0 2000 A 2000 D On September 22, 2010, the Company awarded 2,000 shares of Company common stock as an annual equity grant in the form of restricted stock awards under the Celldex Therapeutics, Inc. 2008 Stock Option Plan, subject to time-based forfeiture restrictions. /s/ Herbert J. Conrad 2010-09-22 -----END PRIVACY-ENHANCED MESSAGE-----